Veracyte, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Marc A. Stapley
- Full Time Employees
- 755
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 6000 Shoreline Court South San Francisco CA United States 94080
- IPO Date
- Oct 30, 2013
- CIK
- 0001384101
- Website
- veracyte.com
- Similar Companies
- Business
- Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that develops and commercializes genomic tests to empower clinicians with precision insights for diagnosing and treating cancer, focusing on pivotal moments in patient care such as avoiding unnecessary surgery, selecting optimal therapies, and monitoring disease progression. The company offers a portfolio of molecular diagnostics through its Veracyte Diagnostics Platform, which leverages broad genomic assays, clinical data, AI-assisted analysis, and evidence generation; core products include the Afirma Genomic Sequencing Classifier and Xpression Atlas for thyroid cancer to reduce unnecessary surgeries; Decipher Prostate Genomic Classifier for localized and metastatic prostate cancer treatment decisions; Decipher Bladder Genomic Classifier for bladder cancer molecular subtyping; Prosigna Breast Cancer Assay for early-stage breast cancer prognosis; Percepta Nasal Swab Test for noninvasive lung cancer risk assessment in CT-detected nodules; and the nCounter analysis system services for decentralized testing. These tests are processed primarily through the company's CLIA-certified laboratories in South San Francisco and San Diego, California, and Austin, Texas, with IVD versions enabling global expansion beyond the United States. Founded in 2006 and headquartered in South San Francisco, California, Veracyte operates in the healthcare sector, specifically biotechnology and diagnostics, serving oncologists, urologists, endocrinologists, surgeons, and pulmonologists across the cancer care continuum. The company targets patients with high-prevalence cancers including thyroid, prostate, bladder, breast, lung, and kidney, generating revenue from testing services, product sales such as Prosigna kits, and biopharmaceutical collaborations. In recent developments, Veracyte completed the acquisition of C2i Genomics in early 2024 for $70 million in stock plus up to $25 million in milestones, integrating whole-genome minimal residual disease (MRD) technology to expand into treatment monitoring and recurrence detection, with the first TrueMRD test for muscle-invasive bladder cancer slated for commercial launch in the first half of 2026. The company launched limited access to Decipher Prostate for metastatic patients in early 2025, broadening its coverage across the prostate cancer risk spectrum, and entered a partnership with Helix to bundle whole exome hereditary cancer testing with Decipher for enhanced therapeutic guidance per NCCN guidelines. Veracyte also reported strong Q3 2025 financial results with 14% revenue growth to $131.9 million, raised its full-year 2025 revenue outlook to $510 million, and advanced its pipeline including Prosigna LDT launch in mid-2026 while achieving 30% adjusted EBITDA margins.
Company News
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
What Veracyte (VCYT) Said on Its Q3 Earnings Call
Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
Veracyte Announces Third Quarter 2026 Financial Results
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Veracyte to Participate in Upcoming Investor Conferences
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Artisan Mid Cap Fund Q3 2026 Portfolio Update
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026